Form 4: Stoke Therapeutics Director Acquires Stock Options

Clare Kahn, a Director at Stoke Therapeutics, Inc., acquired stock options for 30,782 shares.

Summary

• Clare Kahn, a Director at Stoke Therapeutics, Inc. (STOK), was granted stock options on April 3, 2026.
• The options are for 30,782 shares of common stock with an exercise price of $32.79 per share.
• These options are set to expire on April 2, 2036.
• The award vests quarterly, with the first tranche vesting on July 1, 2026, contingent upon continued service.
• Kahn's beneficial ownership of 30,782 shares is direct.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, reflecting standard compensation practices for directors and a commitment to long-term alignment rather than immediate financial performance.

Positives

• Director Clare Kahn has been granted stock options, indicating continued investment and alignment with the company's performance.
• The grant of options suggests management's confidence in future stock appreciation.
• The vesting schedule encourages long-term commitment from the director.

Risks

• The vesting of options is contingent on the reporting person's continued service, meaning any departure before vesting dates could result in forfeiture of unvested options.
• The exercise price of $32.79 implies that the stock price needs to exceed this level for the options to be profitable.

Future Outlook

The vesting schedule of the stock options, with the first tranche vesting on July 1, 2026, and subsequent quarterly vesting, indicates a forward-looking incentive tied to continued service and potential future stock performance.

Industry Context

StockSavvy.ai notes that the issuance of stock options to directors is a common practice in the biotechnology sector, aligning executive incentives with shareholder value creation and encouraging long-term commitment during critical development phases.

Stakeholder Impact

• Shareholders: The alignment of director incentives with stock performance can be viewed positively, potentially leading to decisions that benefit shareholder value.
• Employees: Standard compensation practices for directors can indirectly influence overall company morale and retention strategies.
• Management: Reinforces the importance of continued service for executive compensation.

Next Steps

• Continued service by Clare Kahn through the vesting dates to receive the full benefit of the stock options.
• Monitoring of Stoke Therapeutics' stock price relative to the $32.79 exercise price.

Key Dates

Keywords

Stoke Therapeutics, STOK, Form 4, Stock Options, Director, Beneficial Ownership, Securities, SEC Filing